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Abstract: After the institution of positive-pressure ventilation, the use of noninvasive ventilation 
(NIV) through an interface substantially increased. The first technique was continuous positive 
airway pressure; but, after the introduction of pressure support ventilation at the end of the 20th 
century, this became the main modality. Both techniques, and some others that have been recently 
introduced and which integrate some technological innovations, have extensively demonstrated 
a faster improvement of acute respiratory failure in different patient populations, avoiding endo-
tracheal intubation and facilitating the release of conventional invasive mechanical ventilation. In 
acute settings, NIV is currently the first-line treatment for moderate-to-severe chronic obstructive 
pulmonary disease exacerbation as well as for acute cardiogenic pulmonary edema and should 
be considered in immunocompromised patients with acute respiratory insufficiency, in difficult 
weaning, and in the prevention of postextubation failure. Alternatively, it can also be used in the 
postoperative period and in cases of pneumonia and asthma or as a palliative treatment. NIV is 
currently used in a wide range of acute settings, such as critical care and emergency departments, 
hospital wards, palliative or pediatric units, and in pre-hospital care. It is also used as a home care 
therapy in patients with chronic pulmonary or sleep disorders. The appropriate selection of patients 
and the adaptation to the technique are the keys to success. This review essentially analyzes the 
evidence of benefits of NIV in different populations with acute respiratory failure and describes 
the main modalities, new devices, and some practical aspects of the use of this technique. 
Keywords: noninvasive ventilation, acute respiratory failure, pressure support ventilation, 
CPAP, COPD, acute pulmonary edema
Introduction
Noninvasive ventilation (NIV) refers to the delivery of ventilatory support or positive pres-
sure into the lungs without an invasive endotracheal airway,1,2 usually through a mask. This 
technique has been demonstrated to efficiently improve acute respiratory failure (ARF), 
avoiding the complications associated with endotracheal intubation (EI) and conventional 
invasive mechanical ventilation (IMV), especially ventilator-associated pneumonia.3,4
The main modality is noninvasive pressure support ventilation (NIPSV). Older 
modalities, such as continuous positive airway pressure (CPAP), as well as ones recently 
introduced into the market, have been successfully used in the setting of ARF.5,6 A recent 
survey carried out in USA showed that the use of NIV to treat acute exacerbations of 
chronic obstructive pulmonary disease (COPD) increased more than 400% in one decade 
(from 1% in 1998 to 4.5% in 2008) and was associated with a 42% reduction in IMV.7 
NIV is now a first-line therapy in emergency departments,8 regular hospital wards,9 
palliative10 or pediatric11 care units, and even in out-of-hospital patients.12,13
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We performed a search in PubMed National Library with 
the key words “non-invasive-ventilation.” The search was lim-
ited to: “clinical trials”, “reviews”, “systematic reviews”, and 
“meta-analyses”. All randomized trials and meta-analyses 
were selected. Review articles were chosen according to their 
relevance, based on the author’s reputation and the quality of 
the journal. Nonrandomized trials were also selected from 
these reviews, according to the relevance of the results and 
applying similar criteria.
This review focuses on the following: clinical settings in 
which NIV can be used; modes of NIV; interfaces; ventila-
tors; humidification; when to apply NIV; predictors of failure; 
practical aspects; monitoring NIV; the use of sedation; when 
to stop NIV; and conclusions.
Clinical settings in which NIV  
can be used (indications)
There is strong evidence that the addition of NIV to standard 
care improves outcomes in patients with COPD exacerba-
tion and in those with acute cardiogenic pulmonary edema 
(ACPE);14,15 however, the technique is also used to support 
patients with ARF from other etiologies. There are several 
contraindications to the use of NIV (Table 1) where common 
sense would normally prompt intubation and IMV.16,17
COPD
Acute exacerbations
A significant number of randomized trials have shown an 
improvement in gas exchange and symptoms with the use 
of NIPSV compared to conventional oxygen therapy (COT) 
in patients with COPD exacerbation.18–23 In addition, some 
randomized trials and several meta-analyses or systematic 
reviews confirmed the superiority of NIPSV over COT, in that 
it reduced the EI rate, intensive care unit (ICU) or  hospital 
length of stay, and mortality.24–29 Therefore, NIV should be 
considered a first-line treatment for these patients with COPD 
exacerbation,30–32  especially in those with moderate-to-severe 
decompensation (pH ,7.35 and hypercapnia). To ensure 
better outcomes in terms of intubation and mortality, NIPSV 
should be initiated early, before severe acidosis occurs.14 This 
is especially true in patients treated with NIPSV in general 
wards, as Plant et al demonstrated in a large randomized 
trial.22 The benefit of NIPSV in cases less severe decompensa-
tion (pH $7.35) has not been well established.23,33,34 Though 
pH is by far the most important determinant for deciding 
whether to institute NIPSV, other clinical factors, such as 
tachypnea, the severity of dyspnea, and the use of respiratory 
accessory muscles, should also be considered.35
The rate of NIPSV failure requiring IMV in decompen-
sated COPD patients is low, but, in critical patients, may be 
as high as 60% (5% to 60%).36,37 The short-term outcomes 
of these patients are uncertain. Although some authors 
did not find differences in mortality in patients who failed 
NIPSV compared to those who underwent IMV directly,38 
a registry of patients with COPD exacerbation treated with 
NIV in USA from 1998 to 20087 showed increased mortal-
ity among patients who failed NIPSV. Considering some of 
these variables, close monitoring and expertise is strongly 
recommended when NIPSV is started in patients with a high 
risk of failure.
COPD patients who survive an initial episode of exacer-
bation needing NIV are at high risk for recurrent admission 
and subsequent requirement of NIV.39 In a recent retrospec-
tive analysis of 100 COPD patients with respiratory acidosis 
treated with NIV, Chung et al40 described a median survival 
of 2.08 years, with a mean survival rate at 2 and 5 years 
of 52% and 26%, respectively, significantly higher than in 
some studies from the 1990s41 and closer to that described 
recently by Titlestad et al.42 The only strong predictors of 
5-year mortality were age, body mass index, and domiciliary 
oxygen use. Surprisingly, the degree of acute physiological 
impairment when NIV was initiated was not described as a 
predictor of long-term survival.40
Home mechanical ventilation
In patients with chronic hypercapnic respiratory failure, long-
term NIV can theoretically provide benefits by compensating 
nighttime hypoventilation, allowing respiratory muscles 
to rest, improving nocturnal gas exchange, and resetting 
Table 1 Contraindications of noninvasive ventilation
Absolute Relative
Respiratory arrest Medically unstable (hypotensive 
shock, uncontrolled cardiac 
ischemia, or arrhythmia)
Unable to fit mask Agitated, uncooperative
Uncontrolled vomiting or copious 
upper gastrointestinal bleeding
Unable to protect airway
Total upper airway obstruction Swallowing impairment
Facial trauma excessive secretions not managed 
by secretion clearance techniques
Patient decline Multiple (two or more) organ 
failure
Recent upper airway or upper 
gastrointestinal surgery
Progressive severe respiratory 
failure
Pregnancy
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 central respiratory control in response to arterial partial 
carbon  dioxide pressure (PaCO
2
) concentration. Sleep quality 
improves, as daytime symptoms and patient survival often 
do as well;43,44 however, the long-term benefit from home 
NIV in chronic stable COPD patients remains uncertain, and 
current trials are focused on elucidating which patients may 
benefit from domiciliary NIV and what is the best ventila-
tory strategy.45 A recent meta-analysis including individual 
data from 245 stable hypercapnic COPD patients did not 
find any benefit in 3 or 12 months of nocturnal NIPSV other 
than a slight improvement of PaCO
2
 at 3 months’ follow-up, 
which was more pronounced when NIPSV was applied with 
inspiratory positive airway pressure (IPAP) levels of 18 cm 
H
2
O or higher.46
To date, COPD patients remaining chronically hypercap-
nic after an acute exacerbation, with a greater alteration of 
nighttime ventilation and high adherence to the therapy, seem 
to be the best candidates for home ventilation.44,47 Regarding 
ventilatory modes, trials using low pressure levels in stable 
COPD patients failed to demonstrate improvement in PaCO
2
 
and outcomes.43,48 Conversely, the use of high inspiratory 
pressures (20 to 40 cmH
2
O, known as high-pressure NIPSV) 
in an assisted or controlled mode (high pressures plus a 
respiratory rate beyond the spontaneous rate, known as high-
intensity NIPSV) could play a role in the future, as some 
trials have shown good results.43–50 The reduction in cardiac 
output is more pronounced in high-intensity NIPSV,51 and the 
clinical significance of this effect in patients with preexisting 
cardiovascular disease remains unknown.
ACPe
Either CPAP or NIPSV are used in ACPE.52 Since 1985, 
numerous studies have proved the superiority of CPAP 
(mostly set at 10 cmH
2
O) over standard oxygen therapy in 
patients with ACPE, improving gas exchange and symptoms 
and reducing the EI rate.53–61 Some trials62,63 have shown a 
reduction in the EI rate with NIPSV compared to standard 
therapy, especially in hypercapnic patients.64 No superior-
ity of one technique over the other was shown in clinical 
trials designed to compare both techniques65–72 or in meta-
analyses,15,73–77 although NIPSV tended to show a faster 
improvement in ARF in some studies.
Despite the beneficial effects of NIV in ACPE, the impact 
on mortality still remains unclear. Several meta-analyses con-
ducted in the middle of the last decade73–75 showed a reduc-
tion in mortality with the use of CPAP; however, the Three 
Interventions in Cardiogenic Pulmonary Oedema (3CPO) 
trial,78 the largest clinical trial on NIV carried out to date, 
including more than 1,000 patients and published in 2008, 
did not show differences in 30-day mortality between con-
ventional therapy and NIV, either CPAP, or NIPSV. Although 
a subsequent meta-analysis including the 3CPO trial still 
showed a significant reduction of mortality rate with CPAP 
(relative risk =0.75 [0.61–0.92]),76 the conflicting results 
compared to the large trial makes it difficult to formulate a 
clear conclusion on this issue.
Asthma
Although a favorable response to NIPSV would be anticipated 
in acute asthma, little evidence supports this application.79–83 
Recent reviews concluded that there is not enough evidence 
to support the use of NIPSV in acute asthma and that medi-
cal treatment alone may usually be effective.84,85 The use of 
NIPSV for asthmatic patients who decline intubation and 
for selected patients who are likely to cooperate with mask 
therapy has been suggested, but more data are needed to 
generally recommend this approach.86
Community-acquired pneumonia
The utility of NIV in patients with community-acquired 
pneumonia (CAP) is controversial because some data sug-
gested that delaying EI with NIV could increase mortality;87 
however, several randomized clinical trials have compared the 
efficacy of NIV over COT in patients with CAP,88–90 reporting 
a significant reduction in EI rate, shorter ICU stay, and lower 
mortality, mainly in patients with COPD. Therefore, a trial 
of NIV may be recommended in these patients.
weaning and postextubation respiratory 
failure
NIV has been used in patients with persistent weaning fail-
ure (patients in whom the spontaneous breathing trial failed 
during three consecutive attempts)91 as adjunct to early 
liberation from IMV by shortening the time of IMV and the 
length of stay and lowering the incidence of complications 
(ventilator-associated pneumonia or septic shock).92–99 Early 
extubation and immediate application of NIV when patients 
meet weaning criteria can be a useful approach to increase 
weaning success rates and may reduce mortality in COPD 
patients, but it should be used with caution, as there is no 
strong evidence in terms of avoiding reintubation, even in 
the subgroup of patients with COPD.100
NIPSV can also be used after planned extubation in 
patients at high risk of deterioration (Table 2) as it could 
 prevent postextubation ARF and reintubation.93–95,101 
Recently, Ornico et al102 showed a reduction of reintubation 
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rates when nasal NIV was applied immediately after planned 
extubation (in contrast to oxygen mask) in a small group of 
nonselected patients with more than 3 days with ARF need-
ing IMV. The reintubation rate in the oxygen group was 
high (39%), a fact that could be explained by the particular 
weaning protocol used in this study. More relevant was the 
finding that patients weaned by using NIV had a significantly 
lower hospital mortality compared with patients weaned by 
using COT. These promising results should be confirmed in 
larger, multicenter, randomized trials.
Regarding the role of NIV in treating established ARF 
during the postextubation period (generally 48–72 hours 
after extubation), no trial has reported benefits.103,104 One 
multicenter study104 even found slightly higher mortality in 
the NIV group, which was attributed to delayed reintubation 
(12 hours versus 2.5 hours). This is the main argument as 
to why current guidelines suggest that NIV should not be 
routinely used in patients who have postextubation ARF.105
Other indications
Acute lung injury /acute respiratory distress 
syndrome
Clinical studies and meta-analyses have shown negative 
results with the use of NIV or CPAP in acute lung injury 
(ALI)/acute respiratory distress syndrome (ARDS).106–108 
The delay in EI may be associated with major complications. 
However, patients with initial ALI/ARDS (no multiple organ 
failure or hemodynamic instability) may be treated with NIV, 
avoiding EI in nearly 50% of cases.109
Immunocompromised patients
The use of NIV in ARF of different etiologies in immunocom-
promised patients (patients receiving immunosuppressive 
therapy for solid organ or bone marrow transplant110,111) is 
well supported in terms of significant reduction of EI and 
in-hospital mortality rates. The benefits of NIV compared 
with other ventilatory approaches in patients who have hema-
tological malignancies is controversial, and further research 
is needed to clarify the role of NIV as respiratory support in 
ARF in hematologic patients.112–116
Postoperative respiratory failure
NIV may be used in the postoperative setting to either prevent 
or treat ARF. Although it is not clear whether NIV and CPAP 
may be useful in preventing ARF after low- and high-risk 
surgical procedures,105,117–119 it has been successfully used 
in patients with ARF, presented after abdominal or lung-
resection surgery and reducing EI rate.120,121
Palliative NIv
Palliative NIV can either be administered to offer a chance for 
survival or to alleviate the symptoms of respiratory distress 
in terminal patients.122 Among patients given NIV for ARF 
related to reversible causes, nearly one-half survived and 
returned home.122,123 The use of NIV in patients with dyspnea 
in terminal states is controversial, but it is effective in reducing 
dyspnea and in decreasing the dose of morphine in palliative 
use in patients with end-stage cancer.124 The preservation of 
communication between the patient and the family is con-
sidered one of the main benefits of NIV in this setting. The 
technique is widely used in patients with ARF and a do-not-
intubate order, with frequent use (between 25% and 100% of 
cases) reported by 50% of European physicians.125
Chest trauma
A recent meta-analysis including ten studies with patients 
with chest trauma found that NIV significantly improved 
oxygenation and reduced EI, length of ICU stay, and mortal-
ity (3% deaths in the NIV group compared to 22.9% in the 
control group). In seven of the studies, NIV was used to treat 
ARF, while in the others it was used for ARF prevention.126
Chest wall and neuromuscular disorders
Home NIV can be used in conditions that can lead to chronic 
ventilatory failure such as scoliosis, kyphosis, thoraco-
plasty, muscular dystrophy (Duchenne muscular dystrophy, 
myotonic dystrophy, or poliomyelitis), and motor neuron 
diseases (amyotrophic lateral sclerosis). NIV may improve 
symptom control and quality of life in some of these patients. 
If bulbar function is impaired, tracheostomy ventilation may 
be required, but, in other cases, NIV is preferable.127 Its 
use in rapid progressive neurological disease is, however, 
 controversial, as it could simply protract the dying process 
Table 2 Risk factors for postextubation respiratory failure
Age .65 years.
Cardiac failure as the cause of intubation.
Acute Physiology and Chronic Health evaluation (APACHe) II score .12  
at the time of extubation.
Acute exacerbation of chronic obstructive pulmonary disease.
Chronic respiratory disease with ventilation .48 hours and hypercapnia 
during spontaneous breathing trial.
More than one of the following: 
 Failure of consecutive weaning trials.
 Chronic cardiac failure.
 Arterial partial carbon dioxide pressure .45 mmHg after extubation.
 Multiple comorbidities.
 weak cough or stridor after extubation.
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rather than extend good quality of life.127 In the acute  setting, 
NIV should be used with caution in patients with rapidly 
progressive neuromuscular disease syndromes such as 
myasthenia gravis or Guillain–Barré syndrome, especially 
when bulbar muscles are involved,128 but it can be used to 
treat acute decompensation of chronic respiratory failure 
(ie, respiratory infection).
During bronchoscopy
Although successful experiences in selected centers have 
been reported, the feasibility and safety of diagnostic and 
therapeutic bronchoscopy in NIV is not well known and 
further studies are needed to clarify its impact on intubation 
rates and mortality in high-risk, critically ill patients.129
Obesity hypoventilation syndrome
NIV is considered a significant treatment option for patients 
with obesity hypoventilation syndrome (OHS). Some studies 
have suggested that treatment of OHS with NIV restores sleep 
quality and daytime vigilance and reduces cardiovascular 
morbidity,130 although it is not clear which is the best choice 
of equipment and ventilator settings.130–132 On the other hand, 
patients with OHS often present exacerbations of respiratory 
symptoms that, like COPD with progressive hypercapnia, 
require hospitalization and ventilatory support. By using NIV 
in a similar protocol to that in patients with severe COPD 
exacerbation, it is effective in reducing respiratory acidosis 
and improving respiratory rate.132,133
Obstructive sleep apnea
CPAP is the first-line treatment for moderate-to-severe 
obstructive sleep apnea (OSA) because it eliminates 
obstructive apneic/hypopneic events, resulting in improved 
daytime symptoms and possibly reducing adverse car-
diovascular outcomes.132 On the other hand, it has been 
reported that nearly 50% of patients with chronic heart 
failure have sleep-disordered breathing, which consists of 
OSA caused by upper airway obstruction during sleep and 
Cheyne–Stokes respiration with central sleep apnea caused 
by respiratory control system instability. In these patients, 
the use of NIV (adaptive servoventilation) to compensate 
both abnormalities has been proposed.134
Modes of NIV
As previously mentioned, there are two major modes of NIV: 
CPAP and NIPSV, but many other modes have been used 
and some of them may have a relevant role in the future. An 
epidemiologic survey that included patients who received 
NIPSV for ARF found that pressure support with or without 
positive end-expiratory pressure (PEEP) was used in 67% of 
cases and CPAP was used in 18%.135
CPAP
Although it was introduced earlier in medical practice, it is 
not essentially a “true” ventilation mode because it does not 
provide any inspiratory support.136 CPAP can be generated 
with a simple oxygen source through a hermetical mask with 
a PEEP valve or a Boussignac® (Vygon SA., Ecouen, France) 
mask, which hold a quantity of air in the lungs on expiration. 
The continuous positive intrathoracic pressure recruits col-
lapsed alveolar units and increases functional residual capacity 
and lung compliance, improving oxygenation and the work of 
breathing.52 Control of fraction of inspired oxygen (F
i
O
2
) can 
be difficult, however, unless a mixer or a ventilator is used.
NIPSv
Unlike CPAP, this modality requires a ventilator. It is usually 
programmed with two levels of pressure: expiratory pressure 
(expiratory positive airway pressure [EPAP] or PEEP, similar 
to CPAP) and IPAP (Figure 1). When the patient starts the 
inspiratory effort, the ventilator delivers inspiratory assistance 
with pressure support using a decelerated flow, which keeps 
IPAP constant. When the patient finishes the inspiratory effort 
or the inspiratory flow descends below a preset percentage of 
its maximum value (usually 25%–30%), the pressure support 
is discontinued and the pressure drops down to the predeter-
mined EPAP. In the vast majority of NIV studies in the acute 
setting, the modality used is NIPSV, and this is, by far, the 
most used modality in acute exacerbations of COPD.
Other modalities
Assist-control pressure ventilation
Two levels of pressure (EPAP or PEEP and IPAP) are deliv-
ered as in NIPSV but at a preset respiratory rate. This is the 
modality used in high-intensity NIV.
Proportional assist ventilation
The inspiratory support is regulated by analyzing the elasticity 
and resistance of the patient, delivering an assisted ventilation 
proportional to the patient’s effort. Target volume or pressure 
are not preset. Although this modality has demonstrated a 
better patient–ventilator synchrony,136,137 this advantage has 
not been translated into clinical outcomes.138–140
High-flow nasal cannula
Like CPAP, HFNC does not provide  inspiratory support. The 
system delivers an oxygen–gas mixture that may meet or 
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exceed patients’ spontaneous inspiratory demand, which may 
be up to 35 liters in adult patients with ARF. The main differ-
ence between high-flow nasal cannula (HFNC) and NIPSV 
is that HFNC maintains a fixed flow and generates variable 
pressures depending on the patient’s respiratory pattern, while 
NIPSV provides a variable flow to generate a fixed pressure. 
Three action mechanisms of HFNC are  postulated: first, 
a washout effect in nasopharyngeal dead space, simulating 
the benefits of tracheal gas insufflation; second, a reduction of 
upper airway resistance, which constitutes nearly 50% of total 
airway resistance; and third, a low level of positive intrathoracic 
pressure.141 HFNC can be effectively and safely applied in neo-
nates with respiratory distress, children with bronchiolitis, and 
adults with mild-to-moderate hypoxemic respiratory failure. 
However, no definitive data support that HFNC is equivalent 
or superior to CPAP and the utility of HFNC as an alternative 
to CPAP requires further randomized trials.
Neurally adjusted ventilatory assist
This modality is implemented in some ventilators and is gener-
ally used to facilitate weaning in intubated patients;  however, it 
has also been used as a form of NIV. The device uses a neural 
signal, the electrical diaphragm activity, to trigger and cycle 
off the ventilator, as well as to adapt the amount of pressure 
delivered. This signal occurs earlier than any flow or pressure 
variation,142,143 and pressure is cycled off when diaphragm 
activity ends.144 Neurally adjusted ventilatory assist (NAVA) 
improves patient– ventilation synchrony and has been shown 
to be superior to NIPSV by decreasing ineffective efforts 
and premature and delayed cyclings.142,144 The impact in rel-
evant outcomes remains unclear, however, and the mode has 
important  limitations: first, the system needs the insertion of 
an esophageal catheter; second, changes in patient position can 
deteriorate the signal; third, the neural drive may be affected 
in some diseases or with sedation; and fourth, high NAVA 
gains may cause an irregular respiratory pattern.
Adaptive pressure control
Adaptive pressure control, or average volume-assured pres-
sure support, consists of an adaptive targeting scheme to 
adjust the inspiratory pressure to deliver at least a minimum 
target tidal volume.145 The ventilator provides progressively 
higher or lower pressure support ventilation, according to the 
patient’s inspiratory effort and tidal volume.  Depending on 
the ventilator, this modality has different names  (AutoFlow 
[Evita® XL; Dräger, Lübeck, Germany]; VC+ [Puritan 
 Bennett™ 840;  Covidien plc, Dublin, Ireland]; APV 
[ GALILEO; Hamilton Medical AG, Bonaduz, Switzerland]; 
PRVC [Servo-i and Servo 300; Maquet, Bridgewater, NJ, 
USA]; and average volume-assured pressure support [BiPAP 
Synchrony; Philips Medical Systems, Cleveland, OH, USA]), 
with little differences in their algorithms.145,146 In the acute 
setting, adaptive pressure control has been used in adults with 
COPD and severe hypercapnic encephalopathy (Glasgow 
Coma Scale score ,10), showing better clinical and gaso-
metrical improvement than NIPSV.146
Adaptive servoventilation
Some modern home ventilators have the capability to 
 compensate central apneas with periodic breathing by regula-
tion of the inspiratory and expiratory pressure, treating upper 
airway obstruction by auto-adjustment of the end-EPAP.147 
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Figure 1 Pressure-time curves.
Note: Spontaneous breathing (CPAP: 10 cmH2O) and bilevel PS (IPAP: 22 cmH2O; ePAP: 10 cmH2O) with PS 12 cmH2O. Reproduced from Masip J, Planas K. Noninvasive 
ventilation. In: Tubaro M, Danchin N, Filippatos G, Goldstein P, vranckx P, Zahger D, editors. The ESC Text book of Intensive and Acute Cardiac Care. Oxford: Oxford University 
Press; 2011:215–226.52 By permission of Oxford University Press.
Abbreviations: BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; ePAP, expiratory positive airway pressure; IPAP, inspiratory positive 
airway pressure; PeeP, positive end-expiratory pressure; PS, pressure support.
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This modality has been successfully used to improve sleep 
disturbances in patients with chronic heart failure in whom 
central and peripheral apneas are frequent,148 and in patients 
with complex sleep apnea syndrome, characterized by the 
development of frequent central apneas or a Cheyne–Stokes 
respiratory pattern after initial application of CPAP.147
Negative pressure ventilation
There are few groups still using this modality, usually with 
a cuirass or jacket (poncho), to support patients with chest 
wall disorders.127
Interfaces
Whatever NIV technique is used, an interface is needed to 
connect the patient to a ventilator or to an air/oxygen source 
(Figure 2). Interfaces are devices that connect the ventilator 
tubing to the patient’s face and facilitate the entry of pres-
surized gas into the upper airway. Interface-related problems 
are, by far, the most common reason for NIV intolerance. 
Patient comfort and synchrony are essential when choosing 
an interface, as internal volume is not related to effective 
dead space when NIPSV is delivered.149
Nasal interface
It has been the most commonly used interface in chronic 
respiratory failure (73%), followed by nasal pillow, facial 
masks, and mouth pieces,150 this trend is changing with the 
application of new modes of home NIV, which are usually 
applied with a face mask.47,51 Nasal masks are less useful in 
acute critical situations, generating more resistance151,152 and 
massive leakage through the mouth, often requiring mask 
change.153 On the other hand, they permit speech, feeding, 
coughing, and expectoration, reducing the risk of vomiting.150 
Nasal pillows are a variant that are inserted into the nostrils; 
these are commonly used in pediatric patients.
Face masks
Face masks are the most common interface in clinical practice 
in Europe, used in over 70% of all patients requiring NIV.154 
Disadvantages include lack of protection from vomiting, 
nasal skin injuries, nasal congestion, mouth dryness, eye 
irritation, speaking difficulty, and possible claustrophobia.153 
There are two types of face masks.
Oronasal masks
An oronasal mask covers the mouth and nose. It increases 
minute ventilation and reduces PaCO
2
 more  effectively than 
nasal masks in COPD patients.151 It is the most frequently 
used interface in Europe,154 being indicated specifically in 
mouth-breathing patients with dyspnea.  Different sizes and 
models are necessary to ensure a correct adaptation to the 
patient.
Figure 2 Interfaces for noninvasive ventilation.
Notes: (A) nasal mask; (B and C) oro-nasal masks; (D and E) full-face masks; (F) helmet; (G) nasal pillows. Pictures (A) and (G)  were provided by JM Carratalà from 
H Universitario de Alicante, Spain.
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Total/full-face masks
A total/full-face mask covers the mouth, nose, and eyes. In 
general, little cooperation is required to achieve a correct 
adaptation, with easy fitting and application, and this type 
of mask provokes fewer skin injuries compared to oronasal 
masks.155,156 They may be more comfortable than oronasal 
masks in longer treatments,157,158 although their superiority 
has not been demonstrated.147,159 As total face masks are 
probably the best tolerated, they may become an alternative 
in cases in which mask intolerance is the primary reason for 
failing NIV and should be available in units where NIV is 
routinely applied.157
Helmet
A helmet covers the whole head and part of the neck. It seems 
to provide some advantages over other interfaces: it is well 
tolerated by patients, allows acceptable interaction with the 
environment, and can be used in difficult anatomic situations, 
such as in patients who are edentulous or have facial trauma. 
In contrast to facial masks, helmets do not make contact with 
the patient’s face and therefore do not cause skin lesions.17 
The helmet allows more patient autonomy (speaking, read-
ing, and eating), but the noise can be annoying.160 The use of 
the helmet is not recommended with traditional ventilators, 
as a fresh gas flow high enough to minimize rebreathing is 
necessary.160 It is more appropriate for CPAP because the 
increased dead space may generate asynchrony when NIPSV 
is applied.43,161,162
Other
Mouthpieces placed between lips and held in place by lip seals 
are less effective due to higher leakage and asynchrony rates and 
greater patient discomfort.163,164 Mouth pieces and nasal pillows 
can be applied as a rotating strategy with other interfaces.
Ventilators
There are three types of ventilators for NIPSV: portable ven-
tilators designed specifically for NIV; transport ventilators; 
and ICU ventilators. Classical ICU ventilators (connected to 
air and oxygen gas sources) and transport ventilators (con-
nected to an oxygen source) were primarily configured to 
be used with EI, and provided different levels of monitoring 
and security alarm systems, but often failed during NIPSV 
when leaks were present. Modern ICU ventilators and some 
transport ventilators have solved this drawback by incorpo-
rating NIV algorithms.
In contrast with ICU ventilators, NIV ventilators are 
more economical, easily portable, and do not need an airflow 
source. A wide range of portable ventilators is  currently on 
the market, from the most simple (only pressure is modifiable) 
to the latest generation of high-tech ventilators (monitor-
ing, alarm setting, leakage compensation, different triggers, 
cycling and flow ramp control, etc),165 which allow better 
synchrony than ICU and transport ventilators,  including even 
those with adapted NIV algorithms.165
The most important attribute of the equipment is  leakage 
compensation by means of an increase of airflow (up to 
120–180 L/minute), which maintains tidal volume,  producing 
better patient–ventilator synchrony and higher system 
 efficacy. Since pressure cycling can increase auto-PEEP, 
trigger is usually activated with airflow.166
All the ventilators have particular settings for CPAP. 
 Furthermore, CPAP can be applied without a ventilator using 
the Boussignac mask. The oxygen flows through small-
 diameter channels in cylinder walls and is injected at high 
speed into the cylinder through angled side channels. The 
resulting turbulence, together with air friction, creates pressure 
on the patient’s side cylinder opening, acting as a flow barrier 
or virtual PEEP valve. This is a very simple technique that 
may be used in areas with little equipment (Figure 3).167
Humidification
NIV is often applied without humidifying devices, because 
inspired gases are heated and humidified on the way to the 
alveoli; however, dry gas provokes dryness of the mouth, 
nose, and respiratory tract, resulting in nasal congestion 
and an increase of airway resistance during NIV. Up to 
60% of patients with sleep apnea syndrome using nasal 
CPAP experience nasal congestion and dryness of the nose, 
mouth, and throat.168 Consensus statements and guidelines 
for NIV contain conflicting recommendations concerning 
humidification.169 When it is applied, heat humidification 
is recommended because it seems to facilitate NIV170,171 
by reducing nasal resistance, aiding expectoration, and 
improving adherence and comfort,168 especially in patients 
with respiratory secretions. Heat and moisture exchangers 
are not  indicated when using NIV, since they may increase 
circuit dead space (increased PaCO
2
) and the work of 
breathing.172,173
Where to apply NIV
The clinical benefits of NIV are so relevant in treating some 
patients with ARF that its use has been extended out of the 
ICU and into patient location.
Numerous experiences have been reported in studies 
showing the feasibility and lack of complications using CPAP 
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to treat ACPE in out-of-hospital emergencies,11,174,175 with 
improvement in short-term outcomes.175
Regarding the use of NIV out of the hospital, there are 
insufficient data to recommend its general use.176,177 The 
medical or paramedical personnel-to-patient ratio is higher 
than that usually seen in any hospital department (including 
ICU), often counterbalancing the limitations of space or lower 
skill qualification characteristic of this setting.
NIV is routinely applied in emergency departments in 
the initial period of stabilization and in some specialized 
wards.22,38,178,179 Severely ill patients, however, need a higher 
nurse-to-patient ratio and level of monitoring. Although the 
need for EI is reduced remarkably by NIV, it is not entirely 
abolished, so it is definitely advisable to manage patients 
with more severe ARF in the ICU, where EI can be rapidly 
performed if necessary.16
Predictors of failure and 
complications
Before starting NIV, it is crucial to identify if the patient is a 
good candidate. There is a therapeutic window in which NIV 
should be used, avoiding those patients with mild ARF that 
would easily respond to COT or, conversely, those who pres-
ent very severe ARF needing EI.171 It is necessary to consider 
predictors of failure (Table 3) that warrant closer monitoring, 
paying attention to possible complications like hypotension, 
pneumothorax, gastric insufflation, and vomiting, with the 
risk of aspiration pneumonia. Intubation may be preferred 
if the likelihood of NIV failure is very high. Subjects who 
have a pH ,7.25, an Acute Physiology and Chronic Health 
Evaluation (APACHE) II score .29, and a Glasgow Coma 
Scale score ,11 have failure rates ranging from 64% to 
82%.170,171,180 Patients with excessive respiratory secretions 
or without improvement after 60 minutes of NIV may also 
be at high risk of failure.29,181–183 Clinical signs that are only 
equivocal on presentation become more definitively predic-
tive of failure if they persist after 2 hours of NIV.180
In our experience, there are three levels that may 
influence NIV success: the patient (cause of ARF, patient 
condition, adaptation to NIV); the physician (concomitant 
therapy, expertise in the use of NIV, team attitude); and 
the device (ventilator sets, adequate interface, monitoring 
equipment).
Practical aspects
Clear instructions and frequent encouraging stimuli should 
be given to all patients at the beginning of treatment, often 
while fitting the mask manually.
Figure 3 equipment needed for continuous positive airway pressure Boussignac technique.
Notes: (A) Boussignac valve; (B) oro-nasal mask; nebulization device between (A) and (B); (C) 30-liter oxygen flowmeter; and (D) pressure gauge. The picture containing 
(A) and (B)  was provided by JM Carratalà from H Universitario de Alicante, Spain.
Table 3 Predictors of failure of noninvasive ventilation therapy in 
acute respiratory failure
Before starting After initiation  
NIV
After 60 minutes
Acute respiratory 
distress syndrome
excessive air  
leakage
No reduction in  
respiratory rate
Altered mental  
status
Breathing  
asynchrony with  
the ventilator
No improvement in pH
Shock Bad subjective  
tolerance
No improvement in  
oxygenation
High severity  
scores
Neurological or  
underlying disease  
impairment
No reduction in carbon 
dioxide
Copious secretions Signs of fatigue
extremely high 
respiratory rate
Severe hypoxemia  
in spite of high  
fraction of inspired 
oxygen 
Abbreviation: NIv, noninvasive ventilation.
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ventilator settings
Although clinical guidelines and reviews recommend 
starting with low levels of pressure (IPAP: 8–10 cmH
2
O; 
EPAP: 3–4 cmH
2
O) and increasing pressure support pro-
gressively according to patient adaptation, ensuring expired 
tidal volumes .4–6 mL/kg (it can be lower in COPD 
patients), there are no clinical trials that address the best 
way to start and continue NIPSV. In our experience, these 
initial  parameters are well tolerated at the onset; later, with 
a pressure support of 12–18 cmH
2
O above PEEP, a tidal 
volume of 400–500 mL is commonly reached. Elevated 
pressures may cause  excessive air leakage, asynchrony 
(especially when the patient is tachypneic), and discomfort. 
On the other hand, a PEEP over 4 cmH
2
O is necessary 
to avoid rebreathing when using portable ventilators, 
which may not include an expiratory valve or double 
 inspiratory/expiratory circuit.184 F
i
O
2
 should be titrated to 
achieve the desired oxygen saturation by pulse oximetry 
(.95% in general).
Monitoring NIv
Visualization of flow and pressure waveforms on the dis-
play is strongly recommended. In a recent study, physicians 
obtained a more rapid pH normalization in patients needing 
NIV for COPD exacerbation, with a faster PaCO
2
 reduction in 
the first 6 hours of ventilation, than just controlling numerical 
variables on the display, although the NIV success rate was 
not affected by this ventilatory approach.185
To ensure the success of NIV, close monitoring is 
necessary, especially of respiratory rate (patient’s effort), 
oxygen saturation (to adjust F
i
O
2
), and pH and PaCO
2
 
(to assess  efficacy). In addition to continuous observa-
tion, overall  reassessments are usually performed at 
60 and/or 90–120 minutes. One of the key factors determin-
ing tolerance to NIV (and its  success) is optimal synchrony 
between the patient’s spontaneous breathing activity and 
the ventilator’s set parameters, known as “patient–ventilator 
interaction”. The modality of pressure support ventilation 
unavoidably induces a certain degree of asynchrony, even 
in intubated patients.186 Asynchrony Index (AI) is calculated 
as follows:
 (%) = number of events/(ineffective breaths
+ ventilator cycles) × 100 [1]
An AI .10% is considered severe, leading to an increase 
in the work of breathing and patient  discomfort.186 Although 
several mechanisms may be responsible for asynchrony, air 
leakage is involved in many of them. In general, a leak of 
,0.4 L/second (,25 L/minute) is well tolerated. Asynchrony 
is usually manifested in different forms that each require 
specific approaches.
Trigger asynchrony
Trigger asynchrony is manifested in the form of ineffective 
efforts, double triggering, and auto-triggering. These asyn-
chronies should be managed by tuning the trigger, adjusting 
the level of  pressure support, and reducing the leakage.
Flow asynchrony
Flow asynchrony is manifested when rising time and flow 
cycle are not in accordance with patient’s demand. A shorter 
rise time and higher flow cycle should be considered in 
patients with tachypnea, while slower rise time may be more 
comfortable in patients with low respiratory drive.
Cycle asynchrony
Short cycle (premature cycling off)
Many ventilators have cycling off set at 25%–30% of the 
peak inspiratory flow. By titrating the expiratory trigger, the 
duration of the cycle may be regulated. In COPD patients, it 
is often set at 50%.185
Prolonged cycle (delayed cycling off)
A prolonged cycle is a cycle with a mechanical inspiratory 
time greater than the patient’s inspiratory time. The reduc-
tion of air leaks and/or titration of expiratory trigger, as well 
as setting of maximal inspiratory time, are actions that may 
compensate this asynchrony.
Auto-PeeP
In auto-PEEP, the flow curve does not reach 0 at the end of 
expiration and titration of PEEP (at least until 85% in COPD 
patients) is required to compensate this. 
As a general rule, measures to reduce asynchrony 
should be taken by changing pressure support by steps of 
2 cmH
2
O, and inspiratory and expiratory triggers by steps 
of 5% to 10%.185
The use of sedation
Although sedation can play a role in preventing intoler-
ance to NIV, it is also potentially dangerous because of the 
risk of oversedation. The sedation and analgesic regimens 
that physicians prefer to use during NIV are quite varied. 
 Benzodiazepines (33%) and opiates (29%) are reported 
to be the most often selected sedative agents for NIV.125 
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Morphine, remifentanil, dexmedetomidine, propofol, 
and  midazolam-based regimens have all been used with 
no  serious complications in experienced units.187,188 The 
new α2 adrenoreceptor agonist dexmedetomidine showed 
 similar clinical results to midazolam in decompensated 
COPD with fewer adjustments in its dose,189 and it was 
superior to  midazolam in patients with ACPE intolerant 
to NIV.187
When to stop
NIV is usually stopped when a satisfactory recovery has been 
achieved or, conversely, when there are signs of NIV failure. 
If NIV has been successful, the next step depends on the cause 
and duration of NIV. In mid- or long-term use, a weaning 
period is often carried out, which involves decreasing PEEP 
and ventilatory settings progressively. The application of a 
protocol-directed weaning has shown clear advantages in 
this context.190 This approach does not seem to be necessary 
in short-term use. If the patient deteriorates when NIV is 
interrupted, the therapy is resumed, but, otherwise, NIV may 
be discontinued.180
Conclusion
NIV is the first option for ventilatory support in ARF of 
COPD exacerbations or ACPE and should be considered in 
immunocompromised patients, difficult weaning, and the 
prevention of postextubation failure. It can also be used in the 
postoperative period and in cases of pneumonia and asthma 
or as a palliative treatment. NIV is currently used in a wide 
range of settings, from the ICU to home care. The appropri-
ate selection of patients and the capacity of the team and the 
patients to achieve a proper adaptation to the technique are the 
bottom line for success. Despite no significant technological 
discoveries in the area of ARF in recent years, new ventila-
tory modes and interfaces have recently been introduced 
and others are under development to optimize hospital care, 
home  ventilation, and the control of sleep disorders, further 
expanding the role of NIV in the health system. In conclu-
sion, NIV should currently be considered in the treatment of 
the majority of patients with ARF failure.
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